{"id":79797,"date":"2026-04-21T00:05:14","date_gmt":"2026-04-21T00:05:14","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/"},"modified":"2026-04-21T00:05:14","modified_gmt":"2026-04-21T00:05:14","slug":"enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/","title":{"rendered":"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy"},"content":{"rendered":"<div>\n<ul>\n<li style=\"text-align:justify;\"><b>First\u2011in\u2011class DARKFOX\u2011targeting bispecific T cell engager:<\/b> ENA101 is designed to selectively recognize the DARKFOX\u2011A3 peptide presented by HLA\u2011A*03:01, a highly prevalent HLA allele, enabling precise redirection of T cells to DARKFOX\u2011expressing tumor cells while sparing normal tissues.<\/li>\n<li style=\"text-align:justify;\"><b>Potent and selective T cell\u2013mediated anti<\/b>\u2011<b>tumor activity:<\/b> ENA101 demonstrates robust T cell activation and tumor cell killing with low\u2011picomolar functional potency across multiple DARKFOX\u2011A3\u207a solid tumor models, with no activity observed in antigen\u2011negative controls.<\/li>\n<li style=\"text-align:justify;\"><b>Compelling <i>in vivo<\/i> efficacy at low doses:<\/b> In multiple xenograft models, once\u2011weekly dosing of ENA101 drove complete tumor regression across all dose levels tested, supporting strong translational potential.<\/li>\n<li style=\"text-align:justify;\"><b>Drug-like properties supportive of clinical development:<\/b> ENA101 exhibits high\u2011affinity binding to its target pHLA complex, favorable stability and manufacturability, and an extended plasma half\u2011life enabled by Enara\u2019s proprietary <b>EnTiCE\u00ae<\/b> TCE platform.<\/li>\n<li style=\"text-align:justify;\"><b>Broad clinical relevance of DARKFOX:<\/b> Analyses demonstrate that DARKFOX is highly prevalent and homogeneously expressed across multiple high unmet need solid tumor indications, creating the opportunity for patient selection based on HLA\u2011A*03 positivity alone.<\/li>\n<li style=\"text-align:justify;\"><b>Advancing into clinical development:<\/b> ENA101 is advancing through IND-enabling studies with a clear development path to IND submission in 2H\u20192026.<\/li>\n<\/ul>\n<p><b>Oxford, UK \u2013 April 20, 2026<\/b>.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=extLxVUlCmCa2qdsv9_euvZkmqhoQUufuqEbU2FHBdLmygovKCIbZ6WwUz1S20EbIB6TXTt4Y6eNc6FxRHzEqw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Enara Bio<\/b><\/a>, a pioneer in Dark Antigen\u00ae discovery and bispecific T cell engager (TCE) innovation, today announced the presentation of new preclinical data for ENA101, its first\u2011in\u2011class bispecific T cell engager (TCE), delivered today in an oral session at the American Association for Cancer Research (AACR) Annual Meeting 2026.<\/p>\n<p>ENA101 targets DARKFOX\u00ae, a novel, cancer\u2011specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt\u2011ORF) within FOXM1. \u00a0DARKFOX was discovered and validated using Enara\u2019s proprietary EDAPT\u00ae platform and represents a new class of highly tumor\u2011specific targets derived from the dark proteome.<\/p>\n<p>\u201cENA101 exemplifies the power of uncovering antigens within the dark proteome to overcome long-standing challenges in solid tumor immunotherapy,\u201d said <b>Dr. Joe Dukes, Chief Scientific Officer of Enara Bio<\/b>. \u201cThe data presented today at AACR demonstrate that DARKFOX is a compelling cancer specific target and that ENA101 exhibits the potency, specificity and druglike profile required to advance a best-in-class T cell engager toward the clinic.\u201d<\/p>\n<p>The oral presentation, titled \u201cENA101: A First\u2011in\u2011Class Bispecific T Cell Engager Targeting a DARKFOX Peptide Presented by Solid Tumors,\u201d was delivered <b>by Dr. Joe Dukes in the Advances in Therapeutic Antibodies<\/b> session <br \/>(Abstract #4052). The presentation highlighted the discovery of DARKFOX, the engineering of ENA101, and the comprehensive preclinical dataset supporting its advancement into clinical development.<\/p>\n<p>Enara Bio is currently advancing ENA101 through IND-enabling studies to support IND filing in 2H\u20192026.<\/p>\n<p>The abstract is available in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Mdrn4ZdrCMnJMXnnasj0hPyFHX5HXStRewoFgFTPdlCobLygKoEH3uCMsaazNG2iYezQymcHd2LJDHaX-ddAe5SCkLQBCsF96woihoh4KAjxNFdhnLPRJIcGxQdxqTMncirlvRTKWbPrPgNlS4KItgBKfbMBmmyWv_0QapOgZZwxBS4KbkX5S6lXYxeMUotA2Dq0JmaXw08bNgZsh4v29775-WdiGuikYwMbc_MpvnXczUNsrp0NdW-Hm1PWW2yo9eekt_CTojn8aFu3xfB5439X1ASqxM_MS2XP4U0uugd9ulYIh8tx2uqWcMV6VWe2\" rel=\"nofollow\" target=\"_blank\" title=\"Proceedings of the American Association for Cancer Research Annual Meeting 2026.\">Proceedings of the American Association for Cancer Research Annual Meeting 2026. <\/a><\/p>\n<p><b>About ENA101<\/b><br \/>ENA101 is a first\u2011in\u2011class bispecific T cell engager developed using Enara Bio\u2019s proprietary EnTiCE platform. It incorporates a high\u2011affinity TCR\u2011mimic binder targeting the DARKFOX\u2011A3 peptide, a clinically validated anti\u2011CD3 arm, and an Fc\u2011based architecture for half\u2011life extension, to enable potent, selective and durable anti\u2011tumor immune responses.<\/p>\n<p><b>About Enara Bio<\/b><br \/>Enara Bio is shining a light on Dark Antigen\u00ae and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. Our pioneering EDAPT\u00ae platform enables us to discover cancer-specific antigens, including HLA-presented and cell surface antigens, from previously uncharted genomic \u2018dark matter\u2019. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets on solid tumors. Through our proprietary EnTiCE\u00ae platform, Enara is developing novel bispecific T cell engagers against Dark Antigen targets that are highly prevalent and homogenously expressed across solid tumors. Based in Oxford, UK, Enara Bio is backed by a strong syndicate of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, SV Health Investors, and the Francis Crick Institute.<\/p>\n<p>For more information, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aHIBfEPSLFye27jdzreFDBcI-T9-xF302z850CYUAbfcLHk3DRMMyZOWrWdUpR397k3ML4XqLPojx5pvQnf3sOCsyjM8JvxsdAxgAHVEViU=\" rel=\"nofollow\" target=\"_blank\" title=\"www.enarabio.com\">www.enarabio.com<\/a>.<\/p>\n<p>Dark Antigen\u00ae, DARKFOX&#x2122;, EDAPT\u00ae and EnTiCE\u00ae are trademarks of Enara Bio.<\/p>\n<p><b>Contacts<\/b><br \/>Kevin Pojasek, President &amp; CEO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fetIzrlnwuR0ZKy5IU00pjFNq0GTMJeg6AsVOgKyv8BIPU77AucPcCiSUkKwTlnx8M6aZQDcybPBpPadvEnglV3PPxaUJReJODINUVvM8Qk=\" rel=\"nofollow\" target=\"_blank\" title=\"info@enarabio.com\">info@enarabio.com<\/a><\/p>\n<p>Stacey Davis, CBO &amp; CFO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-VppvVfP7OnvoOhQxRDvxGneHBd3bAp3tYPpM07sF_TGd27GjyWnywodnvAYmfJXTb7eiKQoVXI1sUARsNk46zSBYQya2M37uhKBYuKvZY8Mj4avQc6QKSAn1O2Em9PF\" rel=\"nofollow\" target=\"_blank\" title=\"stacey.davis@enarabio.com\">stacey.davis@enarabio.com<\/a><\/p>\n<p>Frazer Hall, Mark Swallow<br \/>MEDiSTRAVA<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KVI55UX8WQr7idn5iWQMyFKT8ld7kd4QEgm-cLQfMW8ziAEVJu-vPQbM94WqLH95ptnpdLp-COqoZVgOWdFEN1ds2LT_qC-3NAzGa-XA4tcOHoNQJaucAaY5cKJQBGf\" rel=\"nofollow\" target=\"_blank\" title=\"enarabio@medistrava.com\">enarabio@medistrava.com<\/a><\/p>\n<p align=\"center\"><b><br \/><\/b><b>###<\/b><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZjM0Zjc1MzgtY2M4ZS00MTRmLWFiOTktOTEwYjdmMjYyODBiLTcwMDAxMzg3MC0yMDI2LTA0LTIwLWVu\/tiny\/Enara-bio.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>First\u2011in\u2011class DARKFOX\u2011targeting bispecific T cell engager: ENA101 is designed to selectively recognize the DARKFOX\u2011A3 peptide presented by HLA\u2011A*03:01, a highly prevalent HLA allele, enabling precise redirection of T cells to DARKFOX\u2011expressing tumor cells while sparing normal tissues. Potent and selective T cell\u2013mediated anti\u2011tumor activity: ENA101 demonstrates robust T cell activation and tumor cell killing with [&#8230;]\n","protected":false},"author":1,"featured_media":79798,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-79797","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy\" \/>\n<meta property=\"og:description\" content=\"First\u2011in\u2011class DARKFOX\u2011targeting bispecific T cell engager: ENA101 is designed to selectively recognize the DARKFOX\u2011A3 peptide presented by HL\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T00:05:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/04\/sgb-media-kit-2026.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1075\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy\",\"datePublished\":\"2026-04-21T00:05:14+00:00\",\"dateModified\":\"2026-04-21T00:05:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/\"},\"wordCount\":713,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/\",\"name\":\"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-04-21T00:05:14+00:00\",\"dateModified\":\"2026-04-21T00:05:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/","og_locale":"en_US","og_type":"article","og_title":"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy","og_description":"First\u2011in\u2011class DARKFOX\u2011targeting bispecific T cell engager: ENA101 is designed to selectively recognize the DARKFOX\u2011A3 peptide presented by HL","og_url":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-04-21T00:05:14+00:00","og_image":[{"width":1075,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/04\/sgb-media-kit-2026.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy","datePublished":"2026-04-21T00:05:14+00:00","dateModified":"2026-04-21T00:05:14+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/"},"wordCount":713,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/","url":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/","name":"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-04-21T00:05:14+00:00","dateModified":"2026-04-21T00:05:14+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/enara-bio-presents-first-in-class-darkfox-targeting-bispecific-t-cell-engager-ena101-in-oral-presentation-at-aacr-2026-showcasing-breakthrough-potential-in-solid-tumor-immunotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/79797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=79797"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/79797\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/79798"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=79797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=79797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=79797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}